BC1618
BC1618, an orally active Fbxo48 inhibitory compound, stimulates Ampk-dependent signaling (via preventing activated pAmpkα from Fbxo48-mediated degradation) . BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity[1].
Product Specifications
CAS Number
[2222094-18-8]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
AMPK; E1/E2/E3 Enzyme; Mitophagy
Type
Reference compound
Related Pathways
Autophagy; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bc1618.html
Concentration
10mM
Purity
99.74
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC(COC1=CC=C(C(F)(F)F)C=C1)CN(CC2=CC=CC=C2)CC3=CC=CC=C3
Molecular Formula
C24H24F3NO2
Molecular Weight
415.45
Precautions
H302, H315, H319, H335
References & Citations
[1]Yuan Liu, et al. A Fbxo48 inhibitor prevents pAMPKα degradation and ameliorates insulin resistance. Nat Chem Biol. 2021 Mar;17 (3) :298-306.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Human Putative cancer susceptibility gene HEPN1 protein, HEPN1 ELISA Kit
Human Putative cancer susceptibility gene HEPN1 protein, HEPN1 ELISA Kit
Human Putative cancer susceptibility gene HEPN1 protein, HEPN1 ELISA Kit
Human Putative cancer susceptibility gene HEPN1 protein, HEPN1 ELISA Kit